AI & Data Science · Oct 28, 2025Global Health Authorities & AI in the GxP LandscapeAs global health authorities navigate the integration of AI into regulated pharmaceutical environments, distinct regulatory profiles emerge: the FDA leads with strong GxP alignment and a forward-leaning stance on real-world AI applications; the EMA emphasizes ethical oversight and cautious, principle-based adoption; Japan’s PMDA remains conservative, prioritizing patient safety and localized validation; China’s NMPA is accelerating […]Open visual brief